GSK 299423

GSK 299423

Names
IUPAC name 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile
Identifiers
ChemSpider	24751852
Jmol interactive 3D	Image
InChI InChI=1S/C25H27N5O2S/c1-31-20-2-3-23-22(11-20)21(17(12-26)13-29-23)6-9-30-7-4-18(5-8-30)27-14-19-10-25-24(15-28-19)32-16-33-25/h2-3,10-11,13,15,18,27H,4-9,14,16H2,1H3 Key: NKXJSCXEAVZSMF-UHFFFAOYSA-N
SMILES COc1ccc2c(c1)c(c(cn2)C#N)CCN3CCC(CC3)NCc4cc5c(cn4)OCS5
Properties
Chemical formula	C25H27N5O2S
Molar mass	461.58 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB: 2xcs​.

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.^[1][2][3]

No animal studies have been reported. No application has been made for human clinical trials.

References

1. Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010
2. Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs'" Daily Finance, August 6, 2010
3. Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature 466 (7309): 935–40. doi:10.1038/nature09197. PMID 20686482. (primary source)